Nico Van Zandwijk

Nico Van Zandwijk

UNVERIFIED PROFILE

Are you Nico Van Zandwijk?   Register this Author

Register author
Nico Van Zandwijk

Nico Van Zandwijk

Publications by authors named "Nico Van Zandwijk"

Are you Nico Van Zandwijk?   Register this Author

100Publications

1977Reads

50Profile Views

Patterns of care and survival of older patients with malignant pleural mesothelioma.

J Geriatr Oncol 2019 Jul 24;10(4):573-576. Epub 2019 Mar 24.

University of Sydney, Sydney, Australia; Sydney Local Health District, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2019.02.013DOI Listing
July 2019

A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.

J Thorac Dis 2018 Jul;10(7):3909-3921

Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.07.61DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6106007PMC
July 2018

Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.

J Thorac Oncol 2017 09 16;12(9):1421-1433. Epub 2017 Jun 16.

Asbestos Diseases Research Institute, Sydney, Australia; Sydney Medical School, The University of Sydney, Sydney, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.05.024DOI Listing
September 2017

Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes.

Respirology 2017 07 31;22(5):978-985. Epub 2017 Jan 31.

Asbestos Diseases Research Institute, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/resp.12981DOI Listing
July 2017

Malignant mesothelioma in Australia 2015: Current incidence and asbestos exposure trends.

J Toxicol Environ Health B Crit Rev 2016 ;19(5-6):173-189

a Asbestos Diseases Research Institute , University of Sydney , Concord , New South Wales , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10937404.2016.1194254DOI Listing
May 2017

MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients.

Genom Data 2016 Sep 20;9:44-9. Epub 2016 Jun 20.

Asbestos Diseases Research Institute, Sydney, Australia; Sydney Medical School, University of Sydney, NSW, 2000, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gdata.2016.06.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925891PMC
September 2016

Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer.

Epigenomics 2016 08 17;8(8):1079-85. Epub 2016 May 17.

Asbestos Diseases Research Institute, Concord, NSW 2139, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/epi-2016-0035DOI Listing
August 2016

Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.

Eur J Cancer 2016 08 8;63:64-73. Epub 2016 Jun 8.

Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria; Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna, Vienna, Austria; MTA-SE Molecular Oncology Research Group, Hungarian Academy of Sciences, Budapest, Hungary. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.04.018DOI Listing
August 2016

Update in lung cancer: epilogue to a modern review series.

Respirology 2016 Jul 30;21(5):789-90. Epub 2016 May 30.

Asbestos Diseases Research Institute, Concord, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/resp.12809DOI Listing
July 2016

Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972-2009.

Aust N Z J Public Health 2016 Jun 29;40(3):255-62. Epub 2015 Dec 29.

Asbestos Diseases Research Institute, University of Sydney, New South Wales.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1753-6405.12503DOI Listing
June 2016

Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982-2009.

Occup Environ Med 2016 Mar 22;73(3):187-94. Epub 2016 Jan 22.

Asbestos Diseases Research Institute, University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/oemed-2015-103309DOI Listing
March 2016

Using a multidisciplinary approach to combat the burden of asbestos-related disease.

Med J Aust 2016 Feb;204(2):52

Asbestos Diseases Research Institute, Sydney, NSW.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5694/mja15.01209DOI Listing
February 2016

Incidence of malignant mesothelioma in New Zealand and Australia: a global snapshot.

N Z Med J 2015 Dec 18;128(1427):68-71. Epub 2015 Dec 18.

Asbestos Diseases Research Institute (ADRI), Bernie Banton Centre, Gate 3, Hospital Road, Concord Hospital, NSW 2139, Australia.

View Article

Download full-text PDF

Source
December 2015

Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: an evidence-based benchmark for cancer care.

Asia Pac J Clin Oncol 2015 Mar 10;11(1):85-92. Epub 2014 Nov 10.

Asbestos Diseases Research Institute, Sydney, New South Wales, Australia; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, New South Wales, Australia; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.12306DOI Listing
March 2015

MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma.

Mol Oncol 2015 Mar 2;9(3):715-26. Epub 2014 Dec 2.

Asbestos Diseases Research Institute (ADRI), Sydney, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2014.11.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528709PMC
March 2015

Update in lung cancer: prologue to a modern review series.

Respirology 2015 Feb;20(2):183-4

Asbestos Diseases Research Institute, University of Sydney, Concord, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/resp.12457DOI Listing
February 2015

Does miR-1 play a role in malignant pleural mesothelioma development and progression?

Chest 2013 Dec;144(6):1971

Asbestos Diseases Research Institute, Concord, NSW, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1378/chest.13-1657DOI Listing
December 2013

Clinical practice guidelines for malignant pleural mesothelioma.

J Thorac Dis 2013 Dec;5(6):724-5

Asbestos Diseases Research Institute, Gate 3, Hospital Rd, Concord, NSW 2139, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2072-1439.2013.12.50DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886699PMC
December 2013

Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.

J Clin Pathol 2013 Oct 27;66(10):847-53. Epub 2013 Jun 27.

Department of Surgical Pathology, SA Pathology, Flinders Medical Centre, , Bedford Park, South Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2012-201303DOI Listing
October 2013

ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.

J Thorac Oncol 2013 Oct;8(10):1317-28

*Asbestos Diseases Research Institute, University of Sydney, Sydney, Australia; †Department of Anatomical Pathology, Flinders Medical Centre, Adelaide, Australia; ‡Cardiothoracic Surgical Unit, Royal Prince Alfred Hospital; The Baird Institute, Sydney Medical School, University of Sydney, Sydney, Australia; and §Biomedical Research Center, Sir Runrun Shaw Hospital, Zhejiang University, Hangzhou, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182a0840aDOI Listing
October 2013

Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: trends in Australia and a literature review.

Asia Pac J Clin Oncol 2013 Sep 21;9(3):273-9. Epub 2012 Nov 21.

Asbestos Diseases Research Institute, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.12043DOI Listing
September 2013

Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma.

Support Care Cancer 2013 Jul 14;21(7):1879-84. Epub 2013 Feb 14.

Asbestos Diseases Research Institute, Rhodes, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-013-1753-3DOI Listing
July 2013

The Impact of Hemolysis on Cell-Free microRNA Biomarkers.

Front Genet 2013 24;4:94. Epub 2013 May 24.

Asbestos Diseases Research Institute, University of Sydney , Sydney, NSW , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fgene.2013.00094DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663194PMC
June 2013

Cell-free microRNAs: potential biomarkers in need of standardized reporting.

Front Genet 2013 19;4:56. Epub 2013 Apr 19.

Asbestos Diseases Research Institute, University of Sydney Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fgene.2013.00056DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630323PMC
April 2013

Health-related quality of life and inflammatory markers in malignant pleural mesothelioma.

Support Care Cancer 2013 Mar 31;21(3):697-705. Epub 2012 Aug 31.

Department of Medical Oncology, Sydney Cancer Centre, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-012-1569-6DOI Listing
March 2013

Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma.

Clin Lung Cancer 2013 Mar 17;14(2):164-71. Epub 2012 Oct 17.

Asbestos Diseases Research Institute, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2012.09.003DOI Listing
March 2013

The ticking time-bomb of asbestos: its insidious role in the development of malignant mesothelioma.

Crit Rev Oncol Hematol 2012 Nov 27;84(2):200-12. Epub 2012 Mar 27.

Asbestos Diseases Research Institute, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2012.03.001DOI Listing
November 2012

Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools?

Ann Cardiothorac Surg 2012 Nov;1(4):481-6

Asbestos Diseases Research Institute, University of Sydney, PO Box 3628, Rhodes NSW 2138, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2225-319X.2012.10.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3741798PMC
November 2012

Inflammation in malignant mesothelioma - friend or foe?

Ann Cardiothorac Surg 2012 Nov;1(4):516-22

Asbestos Diseases Research Institute, Sydney, Australia; ; University of Sydney, Sydney, Australia; ; Department of Medical Oncology, Sydney Cancer Centre, Sydney, Australia;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2225-319X.2012.10.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3741786PMC
November 2012

Haemolysis during sample preparation alters microRNA content of plasma.

PLoS One 2011 1;6(9):e24145. Epub 2011 Sep 1.

Asbestos Diseases Research Institute, Bernie Banton Centre, University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0024145PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164711PMC
January 2012

Circulating microRNAs: Association with disease and potential use as biomarkers.

Crit Rev Oncol Hematol 2011 Nov 8;80(2):193-208. Epub 2010 Dec 8.

Asbestos Diseases Research Institute (ADRI), Bernie Banton Centre, University of Sydney, Concord, Australia.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S104084281000261
Publisher Site
http://dx.doi.org/10.1016/j.critrevonc.2010.11.004DOI Listing
November 2011

Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study.

Lung Cancer 2011 Nov 24;74(2):274-9. Epub 2011 Mar 24.

Hospital Grosshansdorf, Grosshansdorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2011.02.017DOI Listing
November 2011

Molecular biomarkers in malignant mesothelioma: state of the art.

Pathology 2011 Apr;43(3):201-12

Asbestos Diseases Research Institute, Bernie Banton Centre, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAT.0b013e3283445e67DOI Listing
April 2011

Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoided.

Lung Cancer 2010 May 6;68(2):222-7. Epub 2009 Aug 6.

Department of Surgery, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2009.07.001DOI Listing
May 2010

Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection.

Eur J Cardiothorac Surg 2009 Oct 21;36(4):741-6. Epub 2009 Aug 21.

Department of Surgical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejcts.2009.04.069DOI Listing
October 2009

Individualization of treatment in non-small cell lung cancer.

F1000 Med Rep 2009 Mar 24;1. Epub 2009 Mar 24.

Bernie Banton Centre, University of Sydney Hospital Road, Concord, 2139 NSW Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3410/M1-24DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920715PMC
March 2009

Immunotherapy in non-small-cell lung carcinoma: from inflammation to vaccination.

Clin Lung Cancer 2009 Mar;10(2):99-105

Netherlands Cancer Institution, Antoni Van Leeuwenhoek Hospital, Thoracic Oncology, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLC.2009.n.012DOI Listing
March 2009

Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer.

J Clin Oncol 2008 Sep;26(25):4205-7

Department of Surgical Oncology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.16.3709DOI Listing
September 2008

CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasone.

Lung Cancer 2008 Apr 5;60(1):57-61. Epub 2007 Nov 5.

Department of Pulmonology, VU University Medical Center, Boelelaan 1117, 1081HV Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2007.09.007DOI Listing
April 2008

Influence of heat and moisture exchanger respiratory load on transcutaneous oxygenation in laryngectomized individuals: a randomized crossover study.

Head Neck 2007 Dec;29(12):1102-10

Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute/ Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hed.20643DOI Listing
December 2007

Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer.

J Clin Oncol 2007 Jun;25(18):2534-9

Department of Nuclear Medicine, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2006.10.1337DOI Listing
June 2007

The influence of fluticasone inhalation on markers of carcinogenesis in bronchial epithelium.

Am J Respir Crit Care Med 2007 May 8;175(10):1061-5. Epub 2007 Feb 8.

Department of Pulmonology, VU Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1164/rccm.200612-1770OCDOI Listing
May 2007

Mapping of treatment-induced apoptosis in normal structures: 99mTc-Hynic-rh-annexin V SPECT and CT image fusion.

Eur J Nucl Med Mol Imaging 2006 Aug 4;33(8):893-9. Epub 2006 Apr 4.

Department of Nuclear Medicine, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, CX Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-006-0070-1DOI Listing
August 2006

Relationship between cisplatin administration and the development of ototoxicity.

J Clin Oncol 2006 Feb;24(6):918-24

Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital and Department of Audiology, Academic Medical Center, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2006.10.077
Publisher Site
http://dx.doi.org/10.1200/JCO.2006.10.077DOI Listing
February 2006

Epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) and economics.

Lung Cancer 2006 Jan 1;51(1):137-8. Epub 2005 Dec 1.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2005.08.016DOI Listing
January 2006

Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.

Lung Cancer 2005 Oct;50(1):83-6

Biometrics Department, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2005.04.010DOI Listing
October 2005

Chemoprevention in lung carcinogenesis--an overview.

Eur J Cancer 2005 Sep;41(13):1990-2002

Department of Thoracic Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Plesmanlaan 121, 1066 CX, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2005.05.011DOI Listing
September 2005

Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary?

Clin Cancer Res 2005 Sep;11(18):6608-14

Department of ORL, Academic Medical Center, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-0257DOI Listing
September 2005

Thalidomide in patients with malignant pleural mesothelioma.

Lung Cancer 2005 May 15;48(2):291-6. Epub 2004 Dec 15.

Department of Thoracic Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2004.10.005DOI Listing
May 2005

In vivo imaging of apoptosis by 99mTc-Annexin V scintigraphy: visual analysis in relation to treatment response.

Radiother Oncol 2004 Sep;72(3):333-9

Department of Nuclear Medicine, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2004.07.008DOI Listing
September 2004

Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer.

Clin Cancer Res 2004 Apr;10(7):2237-44

Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Slotervaart Hospital, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
April 2004

Chemoprevention of lung cancer: current status and future prospects.

Lung Cancer 2003 Dec;42 Suppl 1:S71-9

Department of Thoracic Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0169-5002(03)00307-6DOI Listing
December 2003

The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma.

Ann Thorac Surg 2003 Jun;75(6):1715-8; discussion 1718-9

Department of Thoracic Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0003-4975(03)00010-9DOI Listing
June 2003

Chemoprevention of lung cancer: soon daily practice?

Expert Rev Anticancer Ther 2003 Feb;3(1):91-8

Head Dept. Thoracic Oncology, Netherlands Cancer Institute, Amsterdam.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.3.1.91DOI Listing
February 2003

Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLC.

Suppl Tumori 2002 Jul-Aug;1(4):S37-8

Department of Thoracic Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
November 2002

New methods for early diagnosis of lung cancer.

Lung Cancer 2002 Oct;38(1):S9-11

Department of Thoracic Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0169-5002(02)00245-3DOI Listing
October 2002

Chemoprevention strategies for non-small cell lung cancer.

Curr Opin Oncol 2002 Mar;14(2):185-90

Netherlands Cancer Institute, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00001622-200203000-00008DOI Listing
March 2002